RBT JSC is an innovative biotechnology company, developer of the Betusphere platform for the creation and production of subunit vaccines with a high safety profile. The company was established in 2011 for research and development of innovative medicines. It develops complex projects in the field of biopharmaceuticals.
The company's shares are not listed. Trading is carried out on the MOEX OTC market. Purchase of shares is available only to qualified investors.
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential
RBT news
07.05.2025
Board of Directors of Artgen Biotech terminated the agreement with Natsimbio on joint development of RBT vaccine for influenza and covid prophylaxis due to the delay in terms of organizing and conducting clinical trials. Ministry of Health allowed to conduct studies until December 31, 2024, but they never took place. Now RBT will independently prepare a doss...
Source: 
artgen.ru
artgen.ru
11.10.2024
Artgen Biotech Group is investing in the development of a platform for creating new subunit vaccines based on surface recombinant proteins and spherical adjuvant particles. Developer of the technology platform is RBT, a company within the Artgen Biotech group. Total investment in the development of the production component of the platform by RBT, including f...
Source: artgen.ru
artgen.ru
General information
| Company name | RBT |
|---|---|
| Tags | #moex otc, #biotechnology, #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | Moskva, pr-kt Vernadskogo 96 |
| Mailing address | Moskva, pr-kt Vernadskogo 96 |
| Website | rbiotech.ru |
| Information disclosure | e-disclosure.ru |
English (US) 